|Bid||75.43 x 900|
|Ask||75.44 x 1000|
|Day's Range||74.72 - 75.56|
|52 Week Range||68.44 - 83.78|
|Beta (5Y Monthly)||0.41|
|PE Ratio (TTM)||27.27|
|Earnings Date||Jul. 29, 2021|
|Forward Dividend & Yield||2.60 (3.45%)|
|Ex-Dividend Date||Jun. 14, 2021|
|1y Target Est||92.89|
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.
Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.
The U.S. government will pay $1.2 billion for 1.7 billion doses of Merck's experimental oral COVID-19 drug.